SeromYx Systems and ACROBiosystems Announces Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies

Abigail Harris • October 1, 2024

Woburn, MA / Newark, DE – October 1st, 2024 – SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approved anti-CD20 monoclonal antibodies (mAbs). The collaboration leverages SeromYx’s advanced biophysical and cellular Fc-effector function platform and ACROBiosystems’ recombinant human full-length CD20 virus-like particles (VLPs) to provide new insights into the potential drivers of therapeutic safety and efficacy of anti-CD20 mAbs.

CD20, a critical target for treating B-cell malignancies and autoimmune diseases, is selectively expressed on B-cells, allowing for effective B-cell depletion while preserving long-term immune memory. The study compared the biophysical binding and immune effector functions of Rituximab (RTX), Ofatumumab (OFA), and Obinutuzumab (OBZ), providing a detailed analysis of their mechanisms of action.

“This study not only reinforces the importance of comprehensive Fc effector profiling as a critical tool for all mAbs in development, ensuring a deeper understanding of safety and efficacy mechanisms, but also has implications for the development of new anti-CD20 mAbs” said Lenny Moise, VP of Research, at SeromYx.

Robust binding profiles and distinct Fc-effector functions of the anti-CD20 mAbs were observed throughout the study. Notably, the collaboration discovered new Fc-effector functions, including antibody-dependent neutrophil and eosinophil phagocytosis activities. These findings broaden the understanding of how these mAbs engage with immune cells, potentially influencing their efficacy in various clinical settings.

“This collaborative study together with SeromYx represents a significant step in exploring the expansive applications of our human CD20 full-length VLP. We are excited to see how our full-length transmembrane protein contributes to a greater understanding of antibody drug efficacy, driving forward innovations in the field of immunology and more” stated John Miao, Senior VP at ACROBiosystems.

About SeromYx Systems

SeromYx Systems leverages high-throughput cell and bead-based assays, coupled with machine learning computational analysis, to advance the design and development of therapeutic monoclonal antibodies. By profiling the functional interactions between antibodies and innate immune cells, we enable biotechnology and pharmaceutical companies to develop targeted therapies with precision. Our platform provides the most comprehensive Fc effector function profiling to help identify antibody functions for targeting pathogens, infected cells, or tumors.

We offer an extensive suite of biophysical and functional assays to support the entire lifecycle of monoclonal antibody development, from candidate selection to IND and CMC filing. With a GCLP-certified platform and robust data interpretation, SeromYx is a trusted partner in the development of monoclonal therapies that address critical health challenges and unmet medical needs.

About ACROBiosystems

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.

Press Contact:

SeromYx Systems
Abigail Harris
Business Development Manager
abigail.harris@seromyx.com

ACROBiosystems
Peter Hsueh
Marketing Product Manager
Peter.Hsueh@acrobiosystems.com

< Older Post

Newer Post >

Fc-optimized GITR antibody enhances a CD4 T cell–dendritic cell crosstalk to promote antitumor immunity

August 13, 2026

The Fc Review: When you engineer the Fc to enhance one mechanism, what else changes? A recent Nature Cancer study takes a closer look at that question using an agonistic anti-GITR antibody, showing how Fc optimization can influence not only FcγR engagement and Treg depletion, but other immune pathways contributing to antitumor activity. Background: GITR is a stimulatory immune checkpoint receptor being explored as a target for cancer immunotherapy. While agonistic anti-GITR antibodies have shown promise preclinically, clinical efficacy has been limited. Because FcγR engagement can contribute to the activity of these antibodies, the authors used Fc protein engineering and glycoengineering to alter interactions with different human FcγRs and examine how those changes affected antitumor activity. The study highlights: Fc variants with enhanced engagement of activating FcγRIIa or FcγRIIIa increased antitumor activity, while preferentially enhancing engagement of inhibitory FcγRIIb did not improve tumor control. Combining G236A with reduced fucosylation enhanced engagement of both activating FcγRIIa and FcγRIIIa, without enhanced binding to FcγRIIb. This combined variant showed greater antitumor activity than variants enhancing either activating receptor individually in the tested model. Fc-active variants depleted Tregs within the tumor. However, the optimized variant and IgG1 produced similar Treg depletion despite differences in therapeutic activity, pointing to an additional FcγR-mediated mechanism. The Fc-optimized antibody also increased dendritic cell activation, and the authors found that conventional DCs, particularly cDC1s, were required for the Fc-mediated antitumor effect in their models. Further experiments connected this activity to CD4 T cell–DC engagement, with downstream CD4 T cell cytotoxicity and enhanced CD8 T cell activity

C1q and immunoglobulins mediate activity-dependent synapse loss in the adult brain

July 30, 2026

The Fc Review: Stepping a little outside therapeutic antibody and vaccine development this week to highlight a fascinating piece of fundamental antibody biology. A recent Science study uncovers an unexpected role for antibody-mediated complement activity in the adult mouse brain, showing that locally produced IgM and C1q work together to drive activity-dependent synapse elimination. While this work is still early and was performed in mice, it offers an interesting look at how #antibody effector mechanisms may extend beyond the roles we typically think about. Background: Antibodies are typically viewed through the lens of infection, vaccination, or therapeutic development. Their effector functions, including complement activation, are well established as key mechanisms for eliminating pathogens and diseased cells. This study asks whether antibody-mediated complement activity also contributes to normal brain physiology. Using mouse models, the authors investigated how neuronal activity influences complement-mediated synapse remodeling and whether adaptive immune components participate in this process. The study highlights: Increased neuronal activity triggered localized C1q deposition and complement-dependent synapse loss in the adult mouse hippocampus. Activity-dependent recruitment of antibody-secreting B-lineage cells led to local production of antigen-specific IgM, which contributed to C1q deposition at synapses. Reducing neuronal hyperactivity in a mouse model of Alzheimer's disease decreased C1q deposition and partially restored synaptic density. The findings identify a previously unrecognized interaction between adaptive immunity, complement biology, and neuronal circuit remodeling in the adult brain.

Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors

June 26, 2026

The Fc Review: Can better antibody engineering improve safety, not just efficacy? A recent review in Antibody Therapeutics examines how the molecular design of antibody-drug conjugates (ADCs) influences both nonclinical and clinical toxicities, highlighting that safety is determined by far more than the payload alone. Background: ADCs are often discussed in terms of target selection and payload potency, but their safety profile is shaped by the combined properties of the antibody, linker, payload, conjugation strategy, and target biology. This review examines data from marketed ADCs and explores how each component contributes to toxicity, providing a useful framework for designing safer next-generation therapeutics. The study highlights: ADC toxicity is influenced by the combined effects of target antigen expression, antibody structure, linker stability, payload properties, and conjugation technology rather than any single design feature. The Fc region can contribute to off-target toxicity through receptor-mediated uptake. The review discusses roles for Fcγ receptors, FcRn, and C-type lectin receptors in nonspecific internalization that may influence safety. Site-specific conjugation technologies can improve homogeneity, produce more consistent drug-to-antibody ratios (DAR), and enhance stability compared with earlier random conjugation approaches. Properties such as linker stability, payload hydrophobicity, charge, and DAR all influence biodistribution, payload release, and toxicity, underscoring the importance of considering these design variables together.

The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization

June 4, 2026

The Fc Review: When does antibody bivalency help, and when can it work against you? A recent mAbs study explores the impact of antibody bivalency on antigen occupancy and cell surface opsonization, revealing that the same property can be advantageous or disadvantageous depending on the intended mechanism of action (MoA). Background: Most therapeutic antibodies are bivalent, meaning they can bind two target antigens simultaneously. This avidity effect is often viewed as beneficial because it increases apparent binding strength and can improve target engagement. However, therapeutic success is not always driven by target occupancy alone. For mechanisms that rely on Fc-mediated effector function, the number of antibodies decorating the target cell surface may be just as important. The study highlights: Bivalent antibodies achieved higher antigen occupancy than comparable monovalent antibodies across a range of affinities and antigen densities. At the same time, bivalency reduced the total number of antibodies bound per cell because a single antibody could occupy two antigens simultaneously. The authors describe an "avidity barrier," where achieving equivalent levels of cell surface opsonization requires substantially higher concentrations of a bivalent antibody. The optimal balance between occupancy and opsonization depended on factors including antibody affinity, valency, and target antigen density.

RRPV Meeting

June 1, 2026

Type: Meeting Dates: August 26th -27th, 2026 Location: Arlington, VA

11th International Filovirus Symposium

May 29, 2026

Type: Symposium Dates: September 13th-16th, 2026 Location: Atlanta, GA

Food Allergy Science Initiative (FASI)

May 28, 2026

Type: Conference Dates: October 6th-7th, 2026 Location: Boston, MA

A causal link between autoantibodies and neurological symptoms in long COVID

May 28, 2026

Abstract: Acute SARS-CoV-2 infection triggers the de novo production of diverse, functional autoantibodies (AABs) that remain elevated in Long COVID (LC), but their pathogenic role remains unclear. Using tissue-based immunofluorescence, ELISA, human protein array, and mass spectrometry assays, we identified a broad range of AAB targets among individuals with LC. Individuals with neurocognitive symptoms showed increased AABs against central and peripheral nervous system proteins. Purified IgG reacted with human locus coeruleus, thalamus, adrenal gland, thyroid, and cross-reacted with mouse sciatic nerve and meninges. CNS-reactive AABs correlated with several neurological symptoms. MED20-targeting IgG from patients with LC showed enhanced antibody-dependent phagocytosis. Passive transfer of IgG from individuals with LC into mice induced fatigue-like behavior, loss of balance/coordination, thermal hyperalgesia, small fiber nerve damage, and increased pain-related neuronal activity, recapitulating patients’ symptoms. These findings suggest that targeting AABs might offer therapeutic benefits for this LC subgroup.

ISV Annual Congress 2026

May 27, 2026

Type: Conference Dates: October 12th-14th, 2026 Location: Antwerp, Belgium

World Vaccine Congress 2026

May 18, 2026

Type: Conference Dates: October 19th-21st, 2026 Location: Amsterdam, Netherlands